Adaptive Biotechnologies (ADPT) Q1 2023: MRD Test Volume Surges 57%, Fueling Back-Half Growth Setup

May 3, 2023 | By EarningsIQ Research

Adaptive Biotechnologies’ Q1 marked a pivotal inflection in MRD test adoption, with test volumes up sharply and execution on community and blood-based expansion accelerating future revenue visibility. Management reaffirmed full-year guidance and highlighted operational streamlining, while pharma services and drug discovery continued to build diversified growth levers. The company’s focus on disciplined capital allocation and margin improvement signals a measured path toward profitability in 2025 and cash break-even in 2026.

Summary

• MRD Volume Expansion: Record MRD test growth and deeper community penetration are reshaping the business mix.
• Operational Streamlining: Cost reductions and leadership consolidation are aligning execution with profitability goals.
• Long-Term Growth Levers: Pharma partnerships and drug discovery progress are broadening future value creation.

Business Overview

Adaptive Biotechnologies is a precision medicine company leveraging immune-driven sequencing to enable diagnosis, monitoring, and drug discovery. The company operates two primary business segments: MRD (Minimal Residual Disease), a molecular test business for blood cancers, and Immune Medicine, which provides pharma services and drug discovery partnerships. Revenue streams include clinical testing, pharma collaborations, and milestone payments tied to drug development.

Performance Analysis

Q1 results underscored a structural shift toward recurring MRD revenue, which now accounts for the majority of the business. MRD revenue rose 20% year-over-year, with test volume up 57%, driven by strong adoption in both core and emerging indications. Community account contribution increased meaningfully, now representing 18% of ClonoSeq, MRD test, volume, up from 15% last quarter, reflecting effective salesforce targeting and execution. Blood-based testing—a strategic focus for ease of use and broader applicability—grew 30% sequentially, now comprising 35% of all MRD tests.

Immune Medicine revenue was pressured by the anticipated stepdown in Genentech amortization, falling 22% year-over-year, but the underlying pharma services business remains on a double-digit growth trajectory. Operating expenses declined 7% as Adaptive executed on cost discipline, with R&D, sales and marketing, and G&A all lower year-over-year. The company ended the quarter with $441 million in cash, providing ample runway for strategic initiatives and margin expansion efforts.

• MRD Unit Economics Shift: ASP (average selling price) expansion and payer coverage gains are supporting margin improvement.
• Community Channel Growth: Community accounts now contribute nearly one-fifth of MRD test volume, a key lever for future scale.
• Pharma Milestone Pipeline: $400 million in future eligible milestones provides long-term optionality as clinical trials mature.

Management’s guidance reaffirms a back-half weighted year, with MRD and pharma milestones expected to drive sequential acceleration.

Executive Commentary

Strategic Positioning

1. MRD Leadership and Channel Penetration

Adaptive’s ClonoSeq MRD test, its flagship assay for blood cancers, continues to deepen its market leadership, with multiple myeloma and ALL (acute lymphoblastic leukemia) as primary growth drivers. Penetration rates remain low—7-8% in multiple myeloma and 20% in ALL—leaving substantial room for expansion. The company’s salesforce focus on community practices is unlocking underpenetrated channels, with management targeting 50% of MRD volume from community accounts within 3-4 years.

2. Platform Expansion via Blood-Based Testing

Blood-based MRD testing is a critical enabler for broader adoption, offering less invasive sampling and easier integration into routine care. With 35% of MRD tests now blood-based, Adaptive is positioned to benefit from ongoing shifts in clinical practice and payer coverage. Continued data readouts and regulatory milestones are expected to reinforce clinical utility and drive further uptake.

3. Pharma Services and Drug Discovery Diversification

The Immune Medicine segment delivers value through pharma services and drug discovery partnerships, including a marquee collaboration with Genentech in cell therapy. While Genentech amortization is declining, the underlying pharma services business is forecasted to grow 20-30% CAGR over the next 3-5 years. The pipeline of 120+ active studies and $400 million in future milestones provides significant optionality and validates Adaptive’s immune receptor sequencing platform.

4. Operational Efficiency and Cost Discipline

Management is executing on cost controls, consolidating leadership roles and centralizing lab operations to drive margin improvement. Operating expenses fell 7% year-over-year, and a rigorous focus on COGS (cost of goods sold) is underway to support the path to positive EBITDA in 2025. The company is targeting annual OPEX below 2022 levels, with cash burn expected to average $40 million per quarter for the remainder of 2023.

5. Capital Allocation and Strategic Flexibility

Adaptive’s $441 million cash position provides ample strategic flexibility to invest in MRD market expansion, data generation, and next-generation immune medicine programs. The company remains open to external opportunities in solid tumor MRD and leverages its established commercial and pharma channels to evaluate adjacent market entry points.

Key Considerations

This quarter reflects Adaptive’s transition from a research-driven biotech to a scaled, recurring revenue diagnostics and pharma platform, with execution in MRD and disciplined capital allocation as central themes.

Key Considerations:

• MRD Penetration Opportunity: Low current market penetration in key indications leaves a long runway for volume and revenue growth.
• Community Channel Leverage: Expansion into community oncology accounts is a structural growth lever, with significant volume upside as awareness and integration deepen.
• Pharma Services Momentum: The pharma services pipeline and milestone structure offer diversified, high-margin revenue streams, though timing remains lumpy.
• Operational Leverage: Leadership consolidation and lab centralization are expected to yield cost savings and margin gains over time.
• Cash Preservation Focus: Ample liquidity supports ongoing investment in data, R&D, and commercial scale, with a clear path to profitability and cash break-even.

Risks

Adaptive faces execution risk in scaling MRD volumes and achieving payer coverage across all indications, especially as it pushes deeper into community channels and blood-based testing. Pharma services growth may be affected by macro headwinds or pipeline reprioritization among biopharma partners. The timing and realization of milestone payments are inherently uncertain, and any regulatory or reimbursement delays could impact revenue visibility and margin progression.

Forward Outlook

For Q2 2023, Adaptive guided to:

• Continued sequential growth in MRD test volumes, with back-half acceleration expected from Epic integration and DLBCL ramp.
• Operating expenses, including COGS, to remain below 2022 levels.

For full-year 2023, management maintained guidance:

• Total revenue of $205 to $215 million, with 55% from MRD and 45% from Immune Medicine.
• ClonoSeq test volume growth over 50% and mid- to high-single-digit millions in MRD regulatory milestones.

Management highlighted several factors that will shape the year:

• Back-half weighting of revenue driven by new channel integration and product launches.
• Continued cost discipline and focus on margin expansion to support the path to profitability.

Takeaways

Adaptive’s Q1 demonstrates decisive progress in scaling MRD adoption and unlocking new growth levers in both diagnostics and pharma services. The company’s disciplined approach to cost, capital, and operational alignment positions it for sustainable growth and margin improvement.

• MRD Volume Inflection: The 57% YoY test volume surge and deepening community reach signal a structural shift in the business model that increases recurring revenue visibility.
• Strategic Diversification: Pharma partnerships, milestone pipeline, and ongoing drug discovery efforts provide multiple shots on goal for future value creation.
• Profitability Roadmap: Investors should monitor execution on cost initiatives, payer coverage expansion, and milestone realization as key drivers of the path to positive EBITDA and cash break-even.

Conclusion

Adaptive Biotechnologies delivered a strategically significant quarter, with MRD momentum, operational discipline, and diversified growth levers reinforcing its long-term value proposition. The company’s focus on execution and capital efficiency underpins its confidence in achieving both near-term targets and long-term profitability milestones.

Industry Read-Through

Adaptive’s MRD test adoption and pharma partnerships highlight the rising importance of molecular diagnostics and immune profiling in oncology and drug development. The rapid expansion into community channels and blood-based testing reflects broader industry trends toward decentralized, less invasive diagnostics. The $400 million milestone pipeline and ongoing M&A in the MRD space signal robust demand for clinical trial endpoints and companion diagnostics, with implications for peers in liquid biopsy, oncology testing, and pharma services. Investors should watch for continued consolidation and innovation as diagnostics companies expand beyond academic centers and deepen integration with pharma pipelines.

ADPT Health Care Diagnostics Pharma Services MRD Drug Discovery Profitability Community Channel